Prospective phase II trial of first-line rituximab, methotrexate, and orelabrutinib (R-MO) in primary central nervous system lymphoma - Lixia Sheng; Hailing Liu; Xiaohui Zhang; Kaiyang Ding; Jie Ma; Hongling Peng; Xia Zhao; Mei Sun; Wei Shi; Feiyan Zhang; Jianyong Li; Lei Cao; et al. (Blood Cancer Journal, 2025)